DLA PIPER LLP (US) lobbying for BIOTECHNOLOGY INNOVATION ORGANIZATION

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 21, 2025

Income

$60,000.00

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 3

Food & Drug Administration (FDA)
HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 3

HR 946
ORPHAN Cures Act
HR 1262
Mikaela Naylon Give Kids a Chance Act
S 932
Give Kids a Chance Act of 2025

Lobbying activity 4

Medical/Disease Research/Clinical Labs

Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.

Health Issues

Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.

Medicare/Medicaid

Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues.

Pharmacy

340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.